Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Immunocore
AI-generated illustration
OrganisationGB

Immunocore

Oxfordshire biotech whose Kimmtrak became the first approved T-cell receptor drug, in 2022.

Last refreshed: 14 November 2026

Key Question

Can T-cell receptor drugs repeat Kimmtrak's success beyond one tissue type?

Timeline for Immunocore

#17 5 Nov

T-Therapeutics raises $133m in Series B

UK Startups and Innovation
View full timeline →

Background

Immunocore, an Oxfordshire biotech, won US approval in January 2022 for Kimmtrak, the first T-cell receptor drug and the first bispecific T-cell engager approved for a solid tumour. It treats uveal melanoma, but only in patients with the HLA-A*02:01 tissue type, about half of those with the disease.

An Oxford spinout, it raised about $320m privately in 2015, then the largest private financing for a European biotech, and listed on Nasdaq in February 2021. Briefings cite it as the precedent for T-Therapeutics and other British companies working on the same class of molecule.

Common Questions
What is Kimmtrak?
Immunocore's drug for uveal melanoma, approved in the US in January 2022. It was the first T-cell receptor drug to be approved.Source: Lowdown
When did Immunocore go public?
Immunocore listed on Nasdaq in February 2021, after raising about $320m privately in 2015.Source: Lowdown
Which patients can take Kimmtrak?
Only uveal melanoma patients with the HLA-A*02:01 tissue type, about half of those with the disease.Source: Lowdown
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.